1241 ET - Hims & Hers Health's Zava acquisition will expand the company's footprint to major European countries with categories that overlap nicely with its existing offerings, BofA Securities analysts said in a note. However, expanding internationally is a risky move as Hims' core U.S. growth slows. The strategy could reflect product saturation and rising competition domestically. U.S. healthcare technology companies, like Oracle's Cerner and Teladoc's BetterHelp, have had little success in such markets given different regulatory environments in each country. Questions around Hims' future growth prospects remain, the analysts said.(kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
June 03, 2025 12:41 ET (16:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.